Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MeDIP chip from ZOS and ZOSM osteosarcoma cell lines

ABSTRACT: Epigenetic change of genes expression, including hypomethylation-linked activation of oncogenes and hypermethylation-associated inactivation of tumor suppressor genes, can affect almost all the cellular signaling pathways that participate in cancer initiation and progression. Unlike genetic alterations, epigenetic changes are potentially reversible, making them attractive and promising targets for therapeutic intervention. Studies indicated that abnormal DNA methylation is involved in dysregulation of cell cycle, apoptosis, proliferation and differentiation of osteosarcoma. However, epigenetic mechanisms of osteosarcoma metastasis remain largely unknown.

ORGANISM(S): Homo sapiens

PROVIDER: GSE55961 | GEO | 2015/08/25

SECONDARY ACCESSION(S): PRJNA241440

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

MeDIP chip from ZOS and ZOSM osteosarcoma cell lines

Project description:Epigenetic change of genes expression, including hypomethylation-linked activation of oncogenes and hypermethylation-associated inactivation of tumor suppressor genes, can affect almost all the cellular signaling pathways that participate in cancer initiation and progression. Unlike genetic alterations, epigenetic changes are potentially reversible, making them attractive and promising targets for therapeutic intervention. Studies indicated that abnormal DNA methylation is involved in dysregulation of cell cycle, apoptosis, proliferation and differentiation of osteosarcoma. However, epigenetic mechanisms of osteosarcoma metastasis remain largely unknown. MeDIP chips are performed in ZOS and ZOSM—two syngeneic primary human osteosarcoma cell lines with low and high metastatic potential which are established in our lab

2015-08-25 | E-GEOD-55961 | biostudies-arrayexpress

Genetic and epigenetic instability suggest a regulated mechanism for osteosarcoma tumorigenesis

Project description:Osteosarcomas (OS) arise more commonly during the rapid bone growth and remodeling, thus it is plausible to infer the relationship between their tumorigenesis and cell cycle disruption by genetic and epigenetic factors. Methylation data of 28 primary OS was obtained using the HM450K microarray, and compared with nine normal bone tissues. The tumor mutational burden was analyzed using data from the TruSight One sequencing panel. We identified 3,146 differentially methylated positions, and OS presented high methylation heterogeneity, with global hypomethylation and focal hypermethylation at CpG islands. There were 319 hypomethylated and 266 hypermethylated regions in tumors, located in the promoter regions of 172 and 178 genes, respectively. These genes were enriched for biological processes related to skeletal system morphogenesis, proliferation, inflammatory response and signal transduction. Six tumor suppressors presented deletions or hypermethylation (DLEC1, GJB2, HIC1, MIR149, PAX6, WNT5A), and four oncogenes presented gains or hypomethylation (ASPSCR1, NOTCH4, PRDM16, RUNX3). Most cases did not report mutations in DNMTs or TETs, but DNMT3B was recurrently gained, a possible explanation for the hypermethylation at CpG islands. Our analysis also revealed hypomethylation at 6p22, a region that contains several genes, including histones. Overall, aberrant DNA methylation was spread throughout the genome of osteosarcomas, presented with high variance, similar to other molecular alterations. While the open-sea hypomethylation likely contributes to genomic instability, enriched CpG island hypermethylation suggests the involvement of mechanisms related to silencing tumor suppressor genes in osteosarcoma tumorigenesis. These data also suggest DNMT3B probably impacting biological processes associated with early bone development.

2023-06-21 | GSE193000 | GEO

Me-DIP-chip data from osteosarcoma tumours

Project description:Malignant cells show major disruptions in DNA methylation profiles which manifest as aberrant hypermethylation and hypomethylation of gene promoters as well as global genomic hypomethylation. To date, many genes with aberrant promoter hypermethylation have been identified in essentially all forms of cancer including cell cycle regulators, DNA repair genes, genes associated with apoptosis, hormonal regulation, detoxification, metastasis, angiogenesis, and many others We developed an effective high-resolution approach for mapping genome-wide, and cancer-specific DNA methylation profiles. We have used this approach to provide first genomic DNA methylation profiling in human paediatric osteosarcoma tumours

2009-09-08 | GSE12864 | GEO

Me-DIP-chip data from osteosarcoma cell lines

2009-05-01 | GSE11413 | GEO

Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma (ChIP-seq)

Project description:Despite the development of diagnostic and advanced treatment strategies, the prognosis of patients with osteosarcoma remains poor. A limited understanding of the pathogenesis of osteosarcomas has impeded any improvement in patient outcomes over the past 4 decades. It is thus urgent to identify novel effective targets and treatment regimens for osteosarcoma patients. In this study we delineated the super-enhancer landscape in osteosarcoma cells on the basis of H3K27ac signal intensity by ChIP-Seq and found that super-enhancer-associated genes contribute to the malignant potential of osteosarcoma. THZ2, a novel small molecular inhibitor, shows a powerful anti-osteosarcoma ability through suppress super-enhancer-associated genes selectively. Utilizing the characteristics of super-enhancers in cancer cells, we identified 5 critical super-enhancer-associated oncogenes. With the comparative and retrospective analysis in large numbers of human specimens from patients, these 5 oncogenes were observed closely related with patient prognosis. Our findings determined that targeting super-enhancer-associated oncogenes with transcriptional inhibitor, THZ2, was a promising therapeutic strategy in osteosarcoma, and provided novel candidate targets for patients with osteosarcoma.

2019-12-27 | GSE134604 | GEO

Expression Profiling in Human Osteosarcoma

Project description:Osteosarcoma is a rare, highly malignant tumor of the bone that presents with a highly complex and abnormal karyotype. Only a few of the genes, which are targets of genetic alteration are known. An integrated genome-wide genomic and gene expression profiling analysis was performed on human osteosarcoma tissues and osteosarcoma cell lines in order to identify and map, in a high-resolution fashion, the most drastic chromosomal changes and point out genes which could contribute to tumorigenesis by having altered expression levels of critical oncogenes and tumor suppressors. Combined gene expression and aCGH analysis on the same samples enables direct comparison between DNA and mRNA level and offers a general strategy to identify and prioritize potential targets while the parallel analysis on cell lines offers a reliable models for further functional studies.

2016-01-01 | GSE12512 | GEO

Methylation of osteosarcoma patients

Project description:Osteosarcoma is the most common primary malignant tumour of bone occurring in children and young adolescents. Osteosarcoma is characterized by considerable phenotypic and genomic heterogeneity, and few recurrent targetable genetic changes have been reported. Osteosarcoma exhibits a complex karyotype with high genomic and chromosomal instability; and harbours multiple rearrangements across the genome, kataegis and chromothripsis as well as epigenetic changes. Here we have performed DNA methylation profiling on 10 osteosarcoma patient samples and four bones using the Infinium HumanMethylation450 BeadChip from Illumina, covering 485,000 CpG sites across the genome.

2022-01-31 | GSE161407 | GEO

High-resolution profiling of copy-number aberrations in osteosarcoma

2016-01-01 | GSE12789 | GEO

Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma

Project description:Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma

| PRJNA555840 | ENA

Paget's associated osteosarcoma

Project description:Paget's associated osteosarcoma

| PRJNA343233 | ENA